Medicus Pharma Receives Full UK Regulatory and Ethical Approvals to Expand Phase 2 Clinical Study (Sknjct-003) To Non-Invasively Treat Basal Cell Carcinoma

The phase 2 clinical study (SKNJCT-003) which is currently underway in nine (9) clinical sites in United States can now expand into additional sites in United Kingdom